Related Experiment Video

Updated: Jul 17, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Combined targeted therapies in non-small cell lung cancer: a winner strategy?

Tina Cascone1, Cesare Gridelli, Fortunato Ciardiello

  • 1Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Università degli Studi di Napoli, Naples, Italy.

Current Opinion in Oncology
|February 3, 2007
PubMed
Abstract

Insights

Targeted therapies show promise for lung cancer treatment. Combining epidermal growth factor receptor inhibitors with vascular endothelial growth factor inhibitors may improve outcomes in non-small cell lung cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer exhibits significant molecular heterogeneity, necessitating multi-stage therapeutic interventions.
  • Current treatments offer limited improvement, with poor prognosis and potential for therapeutic resistance.
  • Targeting cancer cell proliferation and neoplastic phenotypes requires interfering with multiple signaling pathways.

Purpose of the Study:

  • To review emerging targeted therapies for non-small cell lung cancer (NSCLC).
  • To evaluate the efficacy of novel small-molecule inhibitors and monoclonal antibodies.
  • To explore combination strategies for overcoming therapeutic resistance in advanced NSCLC.

Main Methods:

  • Review of phase I and II clinical trials for targeted agents in NSCLC.
  • Analysis of small-molecule tyrosine kinase inhibitors targeting growth factor receptors.
  • Assessment of combination therapies involving receptor tyrosine kinase inhibitors and monoclonal antibodies.

Main Results:

  • Agents targeting multiple growth factor receptors show encouraging results in early-phase trials.
  • ZD6474 (EGFR/VEGFR2 inhibitor), sorafenib (Raf-1/VEGFR inhibitor), and sunitinib (multi-VEGFR/PDGFR inhibitor) are under investigation.
  • Combination of erlotinib (EGFR-TKI) and bevacizumab (anti-VEGF mAb) demonstrated promise in advanced, refractory NSCLC.

Conclusions:

  • Targeted therapies offer new avenues for NSCLC treatment.
  • Combined inhibition of EGFR and VEGF pathways shows potential in advanced NSCLC.
  • Further research into combination therapies is warranted to improve patient outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...